About Medarex
Medarex is a Healthcare company based in Princeton (United States) founded in 1987, and was acquired by Bristol-Myers Squibb in July 2009. Fully human antibody-based therapeutics to treat cancer and autoimmune diseases. Medarex has completed 1 acquisition, including GenPharm International. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Antibody. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Medarex was established in 1987 in Princeton, United States, within the biotechnology sector. Antibody-based therapeutics were developed by the company to address life-threatening conditions, including cancer, inflammation, autoimmune disorders, and infectious diseases. Operations centered on monoclonal antibodies, with approved products such as Simponi, co-developed with Janssen Biotech for arthritis treatment; ipilimumab for metastatic melanoma; and nivolumab for advanced melanoma.
- Headquarters Princeton, United States
- Stage Acquired
- SectorsHealthcare
- Website medarex.com
- Social LinkedIn
- Acquired by Bristol-Myers Squibb (Jul 2009)
- InvestorsBristol-Myers Squibb
& 1 more
- Investments & Acquisitions
- Acquired byBristol-Myers Squibb
(Jul 2009)
Funding Insights of Medarex
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Medarex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 1998 | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in Medarex
Medarex has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb and Bay City Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for Medarex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Medarex
Medarex has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GenPharm International.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biopharmaceutical products are developed and distributed internationally. | genpharm.com | San Jose, United States | 1989 | May 1997 | $19.3M |
Complete acquisition details for Medarex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Medarex
4 dated milestones of Medarex across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Medarex is founded.
- Acquisition Acquires GenPharm International.
- Funding First funding round.
- Exit Acquired by Bristol-Myers Squibb.
Competitors of Medarex
Medarex has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Medarex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Medarex
Websites that share an audience with Medarex (medarex.com).
Websites whose visitors overlap most with Medarex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thelabrat.com | thelabrat.com | 100% | #5,289,461 | – | |
| yenzym.com | 96% | #6,477,156 | View details | ||
immunodynamics.com | immunodynamics.com | 96% | #12,303,729 | – | |
| chemicon.com | 96% | View details | |||
| immunomedics.com | 96% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Medarex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Medarex (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Medarex
Medarex was founded in 1987 and raised its 1st funding round 11 years after it was founded.
Medarex is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Medarex was established in 1987 in Princeton, United States, within the biotechnology sector. Antibody-based therapeutics were developed by the company to address life-threatening conditions, including cancer, inflammation, autoimmune disorders, and infectious diseases. Operations centered on monoclonal antibodies, with approved products such as Simponi, co-developed with Janssen Biotech for arthritis treatment; ipilimumab for metastatic melanoma; and nivolumab for advanced melanoma.
Medarex's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Medarex has made 1 acquisition, including GenPharm International.
Medarex has 2 investors. Key investors include Bristol-Myers Squibb, and Bay City Capital.
Yes. Medarex was acquired by Bristol-Myers Squibb in July 2009.